How do an elevated index of microcirculatory resistance (IMR) and a reduced coronary flow reserve (CFR) indicate microvascular dysfunction and guide its treatment?

IMR and CFR in Microvascular Dysfunction

An elevated IMR ≥25 units and/or reduced CFR <2.0 definitively diagnose coronary microvascular dysfunction (CMD) and should guide stratified medical therapy with beta-blockers, ACE inhibitors, and statins as first-line treatment to improve symptoms and quality of life. 1, 2

Diagnostic Thresholds and Interpretation

Index of Microcirculatory Resistance (IMR)

• Normal: IMR <25 units
• Abnormal: IMR ≥25 units indicates microvascular dysfunction 3, 1
• IMR is measured during hyperemia using distal coronary pressure (Pd) × mean transit time (Tmn) of a 3 mL room temperature saline bolus
• Key advantage: Less dependent on hemodynamic variations and has better repeatability than CFR 3

Coronary Flow Reserve (CFR)

• Normal: CFR ≥2.0-2.5 (depending on methodology)
• Abnormal: CFR <2.0 indicates impaired microvascular function 1, 2
• Can be measured invasively (catheterization lab) or non-invasively (PET, CMR, transthoracic Doppler echo) 1

Clinical Algorithm for Diagnosis

When to suspect CMD:

1. Clear-cut angina with objective ischemia on stress testing
2. Normal or non-obstructive coronary arteries (FFR >0.80 or <50% stenosis)
3. Persistent symptoms despite no significant epicardial disease 1, 4

Diagnostic pattern recognition:

• Reduced CFR + Elevated IMR = True microvascular disease (structural/functional microvascular dysfunction) 3
• Reduced CFR + Normal IMR = Diffuse epicardial atherosclerosis causing "low-flow" ischemia despite preserved lumen (vessel remodeling) 3
• Normal FFR + Abnormal CFR = Prognostically important discordance suggesting microvascular or diffuse disease 3

Treatment Algorithm Based on Testing Results

For CMD with CFR <2.0 or IMR ≥25 (negative acetylcholine test):

First-line therapy (Class IIa, Level B): 1

• Beta-blockers (e.g., carvedilol 6.25 mg BID, uptitrated) for symptom control
• ACE inhibitors for endothelial dysfunction and symptom control
• Statins regardless of lipid levels
• Lifestyle modifications: weight loss, exercise, smoking cessation

Second-line options:

• Calcium channel blockers
• Ranolazine
• Trimetazidine
• Ivabradine 5, 6

For Microvascular Spasm (positive acetylcholine test without epicardial spasm):

Treat as vasospastic angina: 1

• Calcium channel blockers (Class I, Level A) - may require high doses (diltiazem up to 400-960 mg/day)
• Long-acting nitrates (Class IIa, Level B)
• Nicorandil (where available)
• Avoid beta-blockers in pure vasospastic angina

For Mixed Patterns (overlapping endotypes):

Combination therapy (Class IIb, Level B): 6

• Nitrates + calcium channel blockers + other vasodilators
• May require both dihydropyridine and non-dihydropyridine CCBs

Evidence Quality and Clinical Impact

The 2024 ESC guidelines provide the most recent recommendations (Class IIa, Level A) for stratified medical therapy based on invasive coronary function testing 6. The CorMiCa trial demonstrated that this tailored approach significantly improves angina severity and quality of life compared to standard care 1, 4.

Critical prognostic data: Patients with high FFR but low CFR and high IMR (overt microvascular disease) have significantly worse outcomes, with microvascular disease being an independent predictor of patient-oriented composite outcomes 7. This underscores why identifying CMD matters beyond just symptom management—it affects mortality and morbidity.

Common Pitfalls to Avoid

1. Don't assume normal FFR excludes ischemia: Up to 60% of patients with non-obstructive CAD may have CMD 3

2. Age and gender considerations: Women have higher prevalence of microvascular disease; older patients may have age-related microvascular dysfunction affecting measurements 3

3. Don't use beta-blockers for pure vasospastic angina: This can worsen symptoms through unopposed alpha-receptor stimulation 2, 1

4. Recognize measurement limitations: IMR requires adequate hyperemia (intravenous adenosine preferred); suboptimal hyperemia invalidates results 3, 8

5. Post-PCI microvascular dysfunction: Elevated IMR immediately post-PCI predicts periprocedural myocardial injury and worse outcomes 9, 10

Practical Implementation

Guidewire-based assessment (Class IIa, Level B): 1

• Should be considered in patients with persistent symptoms and angiographically normal or moderate stenoses with preserved FFR/iwFR
• Provides immediate catheterization lab results to guide therapy
• More expensive than pressure-only wires but provides comprehensive physiological assessment 3

The 2023 AHA/ACC guidelines and 2024 ESC guidelines both emphasize that invasive coronary function testing is feasible, safe, and has clear diagnostic utility in identifying specific INOCA endotypes, fundamentally changing management from empirical to targeted therapy 2, 4, 5, 6.